Modality
siRNA
MOA
MDM2i
Target
B7-H3
Pathway
Checkpoint
RettPancreatic Ca
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
→ Jul 2027
Phase 3Current
NCT04447835
336 pts·Pancreatic Ca
2021-12→2025-08·Active
NCT04537675
1,780 pts·Rett
2019-01→2027-07·Terminated
2,116 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-247mo agoPh3 Readout· Pancreatic Ca
2027-07-121.3y awayPh3 Readout· Rett
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2025-08-24 · 7mo ago
Pancreatic Ca
Ph3 Readout
2027-07-12 · 1.3y away
Rett
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04447835 | Phase 3 | Pancreatic Ca | Active | 336 | Safety |
| NCT04537675 | Phase 3 | Rett | Terminated | 1780 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |